Taiwan-based iXensor has announced a partnership with US-based Innova Medical Group, a leading global scale-up platform for rapid screening and diagnosis, with notably more than 2 billion rapid test kits delivered to customers worldwide since its inception in 2020.

Expedited by the COVID-19 pandemic, some medical testing has shifted from central labs to point-of-care and now to consumers' homes as self-testing. iXensor believes its 70 international patents-protected PixoTech technology can play a significant role in addressing the growing demands of smart at-home testing by working with lateral flow assay manufacturers, pharmaceutical partners, and medtech innovators.

Based on the proprietary PixoTech technology and PixoTech XLab, the virtual co-development laboratory, iXensor has developed both At-Home self-test and Point-of-Care testing products across women's health, diabetes, infectious and cardiovascular diseases under Eveline and PixoTest brands that are certified with the US FDA and CE-Mark and sold to global markets across five continents.

"We are delighted to partner with iXensor for the development of our PHRONESIA Smart Ovulation Test with a fully integrated hardware, App and cloud solution, all being manufactured in a cost-effective manner." said Xavier Guerin, President of Europe at Innova Medical Group.